We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.115 | 5.04% | 2.395 | 1,351,173 | 16:35:18 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.27 | 2.52 | 2.30 | 2.27 | 2.27 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | -2.48M | -0.0060 | -3.83 | 9.49M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:26:15 | O | 20,000 | 2.325 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/6/2025 | 12:51 | UK RNS | Immupharma PLC Result of AGM |
| 27/5/2025 | 15:13 | UK RNS | Immupharma PLC Holding(s) in Company |
| 20/5/2025 | 07:00 | UK RNS | Immupharma PLC Notice of AGM |
| 19/5/2025 | 10:37 | ALNC |  Immupharma annual loss narrows as focused on clinical assets |
| 19/5/2025 | 07:00 | UK RNS | Immupharma PLC Final Results |
| 01/4/2025 | 07:00 | UK RNS | Immupharma PLC Extension of Warrants in Incanthera to 30 Sep 2025 |
| 14/3/2025 | 07:00 | UK RNS | Immupharma PLC IMM attending Bio-Europe Spring 17-19 March,Milan |
| 13/3/2025 | 16:27 | ALNC | ImmuPharma celebrates "significant milestone" for P140 platform |
| 13/3/2025 | 07:00 | UK RNS | Immupharma PLC ImmuPharma proves unique Mechanism of Action-P140 |
| 21/2/2025 | 11:36 | UK RNS | Immupharma PLC Holding(s) in Company |
Immupharma (IMM) Share Charts1 Year Immupharma Chart |
|
1 Month Immupharma Chart |
Intraday Immupharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 22/5/2025 | 08:56 | IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES | 39,408 |
| 10/1/2025 | 15:00 | IMM - 16p minimum, due soon | 13 |
| 10/1/2025 | 12:45 | (IMM) ImmuPharma PLC boss excited by “blockbuster potential” of Lupuzor | 82 |
| 10/10/2022 | 13:36 | Immupharma | - |
| 27/7/2022 | 14:08 | IMMUPHARMA - Let's Talk about the Negatives | 389 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 22/6/2025 09:20 by Immupharma Daily Update Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 2.28p.Immupharma currently has 416,437,265 shares in issue. The market capitalisation of Immupharma is £9,578,057. Immupharma has a price to earnings ratio (PE ratio) of -3.83. This morning IMM shares opened at 2.27p |
Posted at 22/5/2025 08:56 by lord loads of lolly I think we can forget about those INC warrants ever adding value to IMM’s coffers now.INC’s “game-changing INC is now forced to dispose of this launch stock via another channel. And whilst Tim can bang on about DTC being higher margin & providing a ready-made customer database (both true), it’s a far less sustainable option for future growth than Watson would have been. IMM holders will be interested to see Tim took months before finally admitting INC’s sole sales partner had walked away. Whilst he recently still listed Avion as a partner to IMM, you have to question how committed / long term this relationship is too, given Tim’s economic & delayed release of any commercial developments. |
Posted at 21/3/2025 08:18 by lord loads of lolly nobby - Avion may well no longer be pursuing. After all, several years have elapsed since the trial was due to start and Tim has studiously avoided any mention of it recently. I think we can deduce that is a possibility- with or without the reply you posted.On the other hand, wouldn’t IMM have been legally obliged to RNS such a market-sensitive development? This new trial was, until the last year or two, IMM’s main hope for the future. I find it unlikely they’d be able to sweep any collapse of said agreement under the carpet. There again, we are talking Tim here….. I guess another possible explanation - assuming the trial with Avion isn’t progressing - is that IMM saw better opportunities elsewhere and decided by mutual consent that they’d prefer to retain the US rights themselves. But again, you’d think this would have to have been RNS’d. As you clearly want to get to the bottom of this, why don’t you follow Kristin’s advice & ask IMM direct? Keep us posted. |
Posted at 18/3/2025 18:23 by nobbygnome Well said super. However IMM could license Lupuzor for other indications to another Pharma, although in that unlikely circumstance I doubt they would get an upfront payment.And wiggy is being deliberately obtuse about the dosing issues. If it was easy then every drug would be dosed and work at the perfect concentration. However in reality there are various bits of evidence which go into trying to choose the correct dose. Pre clinical trials IMM had animal model and in vitro human data. For me the human data is more relevant and that showed they needed at least a 50 fold higher dose but of course an experiment in a little plastic well could be completely different from in vivo in a human and is likely to underestimate the required concentration. In addition the extremely short half-life of a few hours of the Lupuzor peptide adds complexity to the situation. The CSO always claimed that the efficacious concentration is only required for a short period to reset the immune system (which I don’t believe but let’s keep with it for the sake of this argument). So is the required time 10 minures, 2 hours, 5 hours or what. And in which body compartment does it need to be at the required concentration? This is when they changed their tune on where the MOA action was which is laughable because it is actually so crucial. The chances are the key compartment is not blood and is more likely to be deep in some immunological tissue or other (maybe lymph nodes, maybe spleen or ??). So of course the concentration in the tissue is very difficult to determine although it will be comfortably lower than in blood. Therefore you can understand, making an accurate determination of the required dose is very difficult….. However what is obvious from all the studies in animals, in vitro and in humans is that the 200ug dose every 28 days is way way too low…. |
Posted at 18/3/2025 13:25 by jaknife wigwammer,"Old Jak is surprised to find that directors get paid, and bemoans the point that IMM has developed a highly valuable asset that now requires little incremental investment." This supposed "asset" has never generated ANY revenue. To the contrary, it requires regular payments to maintain it. In the English language we call something with such a cash flow profile a "liability"! I don't need to justify my reasons for being negative about IMM, it's plainly and obviously a pile of 💩. * Almost twenty years of zero or negligible revenues * Almost twenty years of regular recurring losses * Almost twenty years of burning cash * Almost twenty years of regular placings * Tens of millions paid to the directors as rewards for failure * no prospect of imminent change to any of the above but... * Success for almost twenty years in exciting shareholders with promises of jam tomorrow which has encouraged them to keep on buying the shares and placings and thus supported the director' lifestyles My favourite quote for this scenario comes from Mark Twain: “It's easier to fool people than to convince them that they have been fooled.” You have been fooled but are too besotted to realise it! Even if we wait a year and point out the (inevitable) failure to achieve anything in the next year, people like you will still make excuses for the director's repeated failure and continue to support them. And then there will be another year, and another year and another ...... JakNife |
Posted at 16/3/2025 14:02 by marketboy Posted by Hosko on the LSE board:------------ Interview on Sunday roast! He confirms the latest announcement is actually the PROOF that we needed! And it’s the only thing the pharma companies needed, just perfectly timed before he flys to Milan! Could this be where he gets the deals done? Deals over £1 billion minimum on all other 11 deals done on autoimmune! Regardless of the share price, I am excited about this one! ------------- |
Posted at 14/3/2025 10:57 by jaknife marmar80,"I meant no new dilution news. They paid 3.75 per share, right?" No. If you read the RNS: 1. Lanstead haven't given any cash to IMM yet. The RNS explains that the £1.875m wasn't actually given to IMM but instead Lanstead kept the cash because it was pledged to them. 2. Lanstead actually agree to give cash to IMM once a month starting in May. 3. The amount that's paid to IMM is £267,857 per month but adjusted to take into account the share price in the four weeks just prior to the payment For example, if the share price averages 3.25p for the four weeks up to the first payment in May then the actual amount paid to Lanstead would be 3.25p / 5.00p * £267,857 = £174,107 Which equates to 2.4375p per share (50m shares / 7 per month) All this means that it is best for Lanstead to dribble stock out on a VWAP basis every month in order to match the terms of the contract that they have with IMM. JakNife |
Posted at 13/3/2025 10:37 by catch007 IMM has a long track record of misleading the market on drug progression ramping up the potential value. McCarthy will use any share price increase via the latest RNS ramp to fund raise again to maintain his opulent lifestyle. The announcement today is interesting to long term holders however lacks detail on how this 'MOA proof if concept' will turn into next steps let alone a pathway to market. |
Posted at 13/2/2025 08:00 by soulac1 are in any share price appreciation over the Benchmark Price (as defined below). However, if the Company's share price is less than the Benchmark Price then the amount received by the Company under the Sharing Agreement will be less than the gross proceeds of the Lanstead Subscription which were pledged by the Company to Lanstead at the outset. |
Posted at 31/1/2025 07:11 by soulac1 From the LSE board This is from our respected 'dallo'. See dallo's post pls."For those newbies who don't understand the Lanstead Agreement the base share price is 2.6p so when the share price is below 2.6p Lanstead pays a monthly payment based on the % below the 2.6p denominator and base monthly payment of £44,000.However if the share price is above the denominator share price of 2.6p the payments increase exponentially.Exampl |
Posted at 28/1/2025 12:59 by sphere25 Told ya....CIRCUS.And now they have had to try to clarify things here following that podcast: ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes the recent movements in its share price. As announced on 9 January 2025, the Company has made innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company's R&D subsidiary ImmuPharma Biotech, has yielded data that provides novel insights into autoimmune disease mechanisms. Through this research, the Company is making a significant step towards personalised medicine in SLE and other autoimmune diseases. (Link: The ImmuPharma team also attended the JP Morgan and Biotech Showcase healthcare conferences earlier this month. Attending both meetings gave the ImmuPharma team the opportunity to continue positive discussions with a number of global BioPharma companies, that have already expressed an interest in P140 and its unique approach to treating autoimmune diseases. ImmuPharma is not aware of any further material commercial or operational reason for the significant share price movements, however, the Company will continue to update the market on developments, both commercially and scientifically, when appropriate, over the next period. So they have clarified what they can, except they haven't clarified alot. Wish I knew if they had the NEXT BIG THING that they say noone else has |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
